top banner image  

topleft corner image     top right corner image
 


bullet

JACC Homepage JACC Imaging Homepage
Still not a subscriber to JACC Imaging or JACC Interventions?

     top nav image

     

J Am Coll Cardiol Intv, 2008; 1:597-598, doi:10.1016/j.jcin.2008.07.006
© 2008 by the American College of Cardiology Foundation
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Shishehbor, M. H.
Right arrow Articles by Whitlow, P. L.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Shishehbor, M. H.
Right arrow Articles by Whitlow, P. L.
Related Collections
Right arrowRelated Article

Letter to the Editor

Improved Survival After Percutaneous Coronary Intervention of Chronic Total Occlusion Varies by Target Vessel

Mehdi H. Shishehbor, DO, MPH*, Patrick L. Whitlow, MD


Safley et al. (1) conducted an important multivariable analysis to determine predictors of success in treating chronic total occlusion and clinical outcomes. As part of their conclusions, they stated that the use of glycoprotein IIb/IIIa was significantly associated with improved success (odds ratio: 2.27, 95% confidence interval: 1.36 to 4.80). However, we feel that the inclusion of glycoprotein IIb/IIIa in models to predict success and outcome is inappropriate, as glycoprotein IIb/IIIa is typically used after and not before the chronic total occlusion has been crossed with a guidewire with reasonable assurance that the wire is intraluminal distally. Therefore, we question whether glycoprotein IIb/IIIa use has any impact on chronic total occlusion success rates. Further, its inclusion in the models can potentially impact the point estimates of other important variables. More importantly, the use of glycoprotein IIb/IIIa before successful crossing of a chronic total occlusion may increase the risk of pericardial effusion or tamponade. It would be of interest to conduct the same analysis without the inclusion of glycoprotein IIb/IIIa to observe whether other important variables are predictive of success and outcome in this cohort.


    Footnotes
 
Please note: Dr. Whitlow has received research grant support from Abbott Vascular, Boston Scientific, and Evalve Inc., and has received consulting fees from Medlogics and Icon International Systems Inc.

* Department of Cardiovascular Medicine, Cleveland Clinic, 9500 Euclid Avenue, JJ40, Cleveland, Ohio 44195 (Email: shishem{at}gmail.com).


    REFERENCES
 Top
 REFERENCES
 

  1. Safley DM, House JA, Marso SP, Grantham JA, Rutherford BD. Improvement in survival following successful percutaneous coronary intervention of chronic total occlusion: variability by target vessel J Am Coll Cardiol Intv 2008;1:295-302.[Abstract/Free Full Text]

Related Article

Reply
David M. Safley, Steven P. Marso, John A. House, J. Aaron Grantham, and Barry D. Rutherford
J. Am. Coll. Cardiol. Intv. 2008 1: 598. [Full Text] [PDF]




This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Shishehbor, M. H.
Right arrow Articles by Whitlow, P. L.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Shishehbor, M. H.
Right arrow Articles by Whitlow, P. L.
Related Collections
Right arrowRelated Article

 
   
 
home link current link search link archive link topics link cardiology careers link